Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846581 | 0.89 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5052768 | 0.88 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1696779 | 0.88 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4950152 | 0.88 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710653 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1585708 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL566228 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16629728 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4280246 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | PHIO PHARMACEUTICALS CORP. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | SYNTHEGO CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-20250283096-A1 | SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE | FLASHPOINT THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250171789-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CureVac SE (DE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025101204-A1 | INTRATUMORAL TARGETING OF PD-1 | PHIO PHARMACEUTICALS CORP. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250099628-A1 | COMPOSITION AND METHODS FOR IMAGING CELLS | UNIV CASE WESTERN RESERVE (US) | 2025-03-27 | — | — | US | disclosed |
| US-12258567-B2 | Artificial nucleic acid molecules | CureVac SE (DE) | 2025-03-25 | — | — | US | disclosed |
| US-20250020645-A1 | A4B1 BINDING APTAMERS | UNIVERSITY OF WASHINGTON (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2024182745-A9 | COMPOSITIONS FOR TARGETING EXTRACELLULAR VESICLE TRAFFICKING AND METHODS THEREOF | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2003106640-A2 | CELL TARGETING METHODS AND COMPOSITIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030054408-A1 | Methods and systems for identifying proteins | RAVI RAMAMOORTHI (US) | 2003-03-20 | — | — | US | disclosed |
| WO-2002086081-A2 | METHODS AND SYSTEMS FOR IDENTIFYING PROTEINS | CARNEGIE MELLON UNIVERSITY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6090932-A | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | PROLIGO LLC (US) | 2000-07-18 | — | — | US | disclosed |
| US-6066484-A | ENZYME WHICH DECOMPOSES NUCLEOSIDES TO FREE BASES AND RIBOSE; FOR REDUCING PURINE LEVELS OF FOODS, INCLUDING BEER, TO PREVENT GOUT AND HYPERURICEMIA | SUNTORY LIMITED (JP) | 2000-05-23 | — | — | US | disclosed |
| EP-0828855-B1 | Oligonucleotide sizing using cleavable primers | STANFORD RES INST INT (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5830655-A | DETERMINATION THE SIZE OF PRIMER EXTENSION | SRI INTERNATIONAL (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0828855-A1 | OLIGONUCLEOTIDE SIZING USING CLEAVABLE PRIMERS | SRI INTERNATIONAL (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0825261-A2 | Purine nucleosidase from Ochrobactrum anthropi | SUNTORY LIMITED (JP) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996037630-A1 | OLIGONUCLEOTIDE SIZING USING CLEAVABLE PRIMERS | SRI INTERNATIONAL (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | CD274, PDCD1LG2, ICOS | SLC28A1 1610/4885SLC28A2 1716/4885SLC29A1 878/4885 |
| US-20250099628-A1 | COMPOSITION AND METHODS FOR IMAGING CELLS | MCL1, TP53, HNRNPAB | SLC28A1 3715/4885SLC28A2 3574/4885SLC29A1 3310/4885 |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | METTL16, NSUN2, RNMT | SLC28A1 437/4885SLC28A2 533/4885SLC29A1 165/4885 |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | DCLRE1B, MRE11, FEN1 | SLC28A1 3946/4885SLC28A2 4060/4885SLC29A1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.